Form 4: Nuvation Bio CSO Granted 748K Stock Options

Nuvation Bio Inc.'s Chief Scientific Officer, Gary Hattersley, was granted 748,130 stock options with an exercise price of $5.91.

Summary

• Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc. (NUVB), was granted 748,130 stock options.
• The transaction date for this grant was February 27, 2026.
• The exercise price for these stock options is $5.91 per share.
• The options will vest as to 25% on the one-year anniversary of February 27, 2026, and monthly thereafter over the subsequent 36 months, contingent on continuous service.
• The expiration date for these stock options is February 26, 2036.
• Following this transaction, Gary Hattersley beneficially owns 748,130 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, primarily due to the alignment of executive incentives with shareholder interests and the retention of key talent. It is a routine compensation disclosure rather than a significant operational or financial update.

Positives

• The grant of stock options aligns the Chief Scientific Officer's long-term incentives with shareholder value, encouraging retention and performance.
• This is a standard component of executive compensation, indicating a commitment to key personnel.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an executive compensation event.

Industry Context

Stock option grants are a common and widely accepted form of executive compensation in the biotechnology and pharmaceutical industries. They are designed to incentivize long-term performance, retain key talent, and align the interests of executives with those of shareholders, particularly in sectors with long development cycles and high R&D costs like biotech. StockSavvy.ai notes this grant is consistent with typical compensation structures for senior scientific officers in publicly traded life sciences companies.

Comparison to Industry Standards

• The grant of stock options to a Chief Scientific Officer is a standard practice for executive compensation across the biotech and pharmaceutical industries.
• The vesting schedule, with an initial one-year cliff followed by monthly vesting, is a common structure designed to encourage long-term commitment and retention.
• The exercise price being set at the market price on the grant date is typical for incentive stock options.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term company performance and value creation.
• Employees (specifically Gary Hattersley): Direct positive impact through increased equity ownership and long-term incentive compensation.

Next Steps

• The stock options will begin vesting on February 27, 2027, with subsequent monthly vesting over 36 months.
• Gary Hattersley may exercise the vested options at the specified exercise price before the expiration date of February 26, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a key executive, which is a standard compensation practice. It does not provide new operational or financial data to alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Nuvation Bio, NUVB, Stock Option, Form 4, Insider Transaction, Gary Hattersley, Chief Scientific Officer, Equity Grant, Executive Compensation